I(eye)-SCREEN: A real-world AI-based infrastructure for screening and prediction of progression in age-related macular degeneration (AMD) providing accessible shared care

I(eye)-SCREEN：基于人工智能的现实基础设施，用于筛查和预测年龄相关性黄斑变性 (AMD) 的进展，提供可及的共享护理

• 批准号: 10102692
• 金额: $ 41.25万
• 依托单位: QUEEN'S UNIVERSITY OF BELFAST
• 依托单位国家: 英国
• 项目类别: EU-Funded
• 财政年份: 2024
• 资助国家: 英国
• 起止时间: 2024 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10102692
• 关键词: eye; SCREEN; real; world; AI

The aim of I(eye)-Screen is to develop an artificial intelligence (AI)-based diagnostic decision support system for screening and monitoring of age-related macular degeneration (AMD) at an early stage before vision loss occurs. Late AMD is the leading cause of legal blindness >50 years with 110 mio individuals at risk. The multidisciplinary consortium brings together a network of clinical retina experts, computer scientists working at the cutting edge of AI development, an infrastructure of community-based opticians/optometrists and an SME experienced in digital platform performance to develop innovative and trustworthy AI tools for broad, real-time AMD screening and monitoring via a cloud-based infrastructure with unlimited access. To achieve the ambitious goal of finding “the needle in the haystack” in early AMD, Optical Coherence Tomography (OCT), a high-resolution, effortless imaging modality is used providing a detailed characterization of the retina in extensive volumetric scans. Breakthrough AI approaches for medical imaging will be developed to enable data-efficient and robust learning from sparse longitudinal OCT data to systematically analyse dense data volumes and identify (sub)clinical markers of disease activity. Clinical sites throughout Europe will collect a longitudinal cohort serving for calibrating and fine-tuning algorithms using the high-end OCT device available at eye clinics. Innovative AI technology will then be created to transferthe detection and monitoring tools to low-cost devices used in next door opticians’/optometrists’ offices. The timing of the project perfectly fits the recent regulatory approval of the first therapy to halt progression of the major atrophic type of AMD. The resulting AIbased “shared care” strategy offers unrestricted accessibility to vision-maintaining care with greatest health equity and provides a role model for screening for systemic, cardiovascular and neurodegenerative disease reflecting retinal biomarkers.

I（眼）屏幕的目的是开发基于人工智能（AI）的诊断决策支持系统，以在发生视力丧失之前的早期阶段筛查和监测与年龄相关的黄斑变性（AMD）。晚期AMD是法律失明> 50年的主要原因，有110名MIO人有危险。多学科联盟汇集了一个临床视网膜专家的网络，在AI开发的最前沿工作的计算机科学家，基于社区的光学师/验光师的基础设施以及在数字平台性能中经验丰富的中小型企业，以开发创新和可信赖的AI工具，可通过基于云的基础范围访问云基础访问，以通过云基础访问进行广泛的AMD筛选和监视。为了实现雄心勃勃的目标，即在早期AMD中找到“在干草堆中的针头”（Optical Cooherence断层扫描（OCT）），使用了高分辨率，轻松的成像方式，可在广泛的体积扫描中对视网膜进行详细的表征。将开发出AI的突破性AI方法，以从稀疏的纵向OCT数据中启用数据效率和稳健的学习，以系统地分析密集的数据量并识别疾病活动的（子）临床标志物。整个欧洲的临床部位将收集使用Eye Clinics可用的高端OCT设备校准和微调算法的纵向队列。然后，将创建创新的AI技术，以将检测和监视工具转移到隔壁的光学师/验光师办公室中使用的低成本设备。该项目的时机完全符合最新的监管部门对制止主要萎缩类型AMD的进展的法规批准。由此产生的AIB“共享护理”策略提供了最大的健康公平的不受限制的可访问性维护维护护理，并为反映视网膜生物标志物的全身，心血管和神经退行性疾病提供了筛查的榜样。